AlphaGrep UK’s Adaptive Biotechnologies ADPT Stock Holding History

AlphaGrep UK’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,508	Closed	-$229K	–	727
2026 Q1	$229K	Buy	+16,508	New	+$263K	0.07%	653

Other funds holding ADPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AlphaGrep UK's ADPT Position: Q2 2026 in Review

AlphaGrep UK sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 16,508 shares — an estimated $229K sold.

AlphaGrep UK first reported a position in ADPT in Q1 2026 and held it in 1 quarter. The position peaked at $229K in Q1 2026. 280 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

AlphaGrep UK reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
AlphaGrep UK sold 16,508 Adaptive Biotechnologies shares in Q2 2026, an estimated $229K.
AlphaGrep UK first reported a position in Adaptive Biotechnologies in Q1 2026 and held it in 1 quarter.
AlphaGrep UK's Adaptive Biotechnologies position peaked at $229K in Q1 2026.
280 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on AlphaGrep UK's 13F filing for Q2 2026, filed 14 Aug 2026.